Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis

[1]  D. Rader,et al.  Statins and Cognitive Function: A Systematic Review†∗ , 2014 .

[2]  M. Blaha,et al.  Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. , 2013, Mayo Clinic proceedings.

[3]  M. Pugh,et al.  Statins and musculoskeletal conditions, arthropathies, and injuries. , 2013, JAMA internal medicine.

[4]  Huseyin Naci,et al.  Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials , 2013, Circulation. Cardiovascular quality and outcomes.

[5]  E. S. Ng,et al.  The efficiency of cardiovascular risk assessment: do the right patients get statin treatment? , 2013, Heart.

[6]  Tara Gomes,et al.  Risk of incident diabetes among patients treated with statins: population based study , 2013, BMJ.

[7]  K. Sanderson,et al.  The impact of statins on psychological wellbeing: a systematic review and meta-analysis , 2012, BMC Medicine.

[8]  P. Thompson,et al.  Effect of Statins on Skeletal Muscle Function , 2012, Circulation.

[9]  R. Collins,et al.  Statins for people at low risk of cardiovascular disease – Authors' reply , 2012, The Lancet.

[10]  J. McMurray,et al.  Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials , 2012, PLoS medicine.

[11]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[12]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[13]  P. Ridker,et al.  The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial , 2012, Canadian Medical Association Journal.

[14]  Xiang Gao,et al.  Prospective study of statin use and risk of Parkinson disease. , 2012, Archives of neurology.

[15]  Su Golder,et al.  Sensitivity and precision of adverse effects search filters in MEDLINE and EMBASE: a case study of fractures with thiazolidinediones. , 2012, Health information and libraries journal.

[16]  J. Manson,et al.  Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. , 2012, Archives of internal medicine.

[17]  John Simes,et al.  Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy , 2012, PloS one.

[18]  A. Hofman,et al.  Cholesterol-Lowering Drugs and Incident Open-Angle Glaucoma: A Population-Based Cohort Study , 2012, PloS one.

[19]  Heart Protection Study Collaborative Group.  Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial , 2011, Lancet.

[20]  R. Cavallazzi,et al.  Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies , 2011, European Journal of Clinical Pharmacology.

[21]  Eric E. Smith,et al.  Statins and Intracerebral Hemorrhage: Collaborative Systematic Review and Meta-Analysis , 2011, Circulation.

[22]  H. van Loveren,et al.  Use of statins is associated with an increased risk of rheumatoid arthritis , 2011, Annals of the rheumatic diseases.

[23]  K. Nakashima,et al.  [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[24]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[25]  Ronald Klein,et al.  The prevalence of hearing impairment and associated risk factors: the Beaver Dam Offspring Study. , 2011, Archives of otolaryngology--head & neck surgery.

[26]  Su Golder,et al.  Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview , 2011, PLoS medicine.

[27]  P. Barter,et al.  Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. , 2011, Journal of the American College of Cardiology.

[28]  P. Macfarlane,et al.  Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials , 2011, BMJ : British Medical Journal.

[29]  M. Quon,et al.  Differential metabolic effects of distinct statins. , 2011, Atherosclerosis.

[30]  V. Roger,et al.  Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms , 2011, BJU international.

[31]  E. Akl,et al.  Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. , 2011, QJM : monthly journal of the Association of Physicians.

[32]  H. Sørensen,et al.  Long-term statin use and the risk of gallstone disease: A population-based case-control study. , 2011, American journal of epidemiology.

[33]  S. Yusuf,et al.  The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. , 2010, Circulation.

[34]  E. Kua,et al.  Statin use and depressive symptoms in a prospective study of community‐living older persons , 2010, Pharmacoepidemiology and drug safety.

[35]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[36]  J. Olsen,et al.  Statin use and Parkinson's disease in Denmark , 2010, Movement disorders : official journal of the Movement Disorder Society.

[37]  D. Cook,et al.  Hypotensive medication, statins, and the risk of glaucoma. , 2010, Investigative ophthalmology & visual science.

[38]  G. Schellenberg,et al.  Age‐Varying Association Between Statin Use and Incident Alzheimer's Disease , 2010, Journal of the American Geriatrics Society.

[39]  P. Passmore,et al.  Statins for the treatment of dementia , 2010, Alzheimer's & Dementia.

[40]  H. Sørensen,et al.  Statin Use and Risk of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders , 2010, Circulation. Cardiovascular quality and outcomes.

[41]  Carol Coupland,et al.  Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database , 2010, BMJ : British Medical Journal.

[42]  M. Hayden,et al.  Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice , 2010, Diabetologia.

[43]  C. Cooper,et al.  Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study. , 2010, Age and ageing.

[44]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[45]  D M Fleming,et al.  An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998–1999 to 2005–2006 , 2010, Epidemiology and Infection.

[46]  D. Redelmeier,et al.  Influenza Morbidity and Mortality in Elderly Patients Receiving Statins: A Cohort Study , 2009, PloS one.

[47]  Vineet Chopra,et al.  Does statin use improve pneumonia outcomes? , 2009, Chest.

[48]  Isabelle Boutron,et al.  Reporting of safety results in published reports of randomized controlled trials. , 2009, Archives of internal medicine.

[49]  W. Niessen,et al.  Withdrawal of Statins and Risk of Subarachnoid Hemorrhage , 2009, Stroke.

[50]  S. MacDonald,et al.  Serum total cholesterol, statins and cognition in non-demented elderly , 2009, Neurobiology of Aging.

[51]  T. Fujii,et al.  Statin use and risk of gastroduodenal ulcer and reflux esophagitis. , 2009, Hepato-gastroenterology.

[52]  W. Willett,et al.  Statin use and the risk of cholecystectomy in women. , 2009, Gastroenterology.

[53]  R. Hubbard,et al.  Risk of community‐acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population‐based case–control study , 2009, Pharmacoepidemiology and drug safety.

[54]  E. Horváth-Puhó,et al.  Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study , 2009, Journal of thrombosis and haemostasis : JTH.

[55]  J. Hallas,et al.  Do statins protect against upper gastrointestinal bleeding? , 2009, British journal of clinical pharmacology.

[56]  F. Rosendaal,et al.  HMG‐CoA reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.

[57]  M. Wallander,et al.  Chronic Obstructive Pulmonary Disease in UK Primary Care: Incidence and Risk Factors , 2009, COPD.

[58]  A Hofman,et al.  Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[59]  J. Witteman,et al.  Cerebrovascular risk factors and incident depression in community‐dwelling elderly , 2008, Acta psychiatrica Scandinavica.

[60]  J D Kalbfleisch,et al.  Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study , 2008, Neurology.

[61]  I. McInnes,et al.  Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[62]  B. Ritz,et al.  Statin use and the risk of Parkinson disease , 2008, Neurology.

[63]  J. Mehta,et al.  Effect of statins on the development of renal dysfunction. , 2008, The American journal of cardiology.

[64]  A. LaCroix,et al.  Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women's Health Initiative Observational Study. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[65]  C. Wolfson,et al.  Lipid-Lowering Agents and the Risk of Cognitive Impairment That Does Not Meet Criteria for Dementia, in Relation to Apolipoprotein E Status , 2007, Neuroepidemiology.

[66]  J. Armitage,et al.  The safety of statins in clinical practice , 2007, The Lancet.

[67]  K. Hall,et al.  Association of statin use with cognitive decline in elderly African Americans , 2007, Neurology.

[68]  G. Nichols,et al.  Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. , 2007, Clinical therapeutics.

[69]  J. Hokanson,et al.  Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. , 2007, Journal of clinical epidemiology.

[70]  R. Klein,et al.  Statin use and the five-year incidence and progression of age-related macular degeneration. , 2007, American journal of ophthalmology.

[71]  S. Hernández-Díaz,et al.  Statins and fracture risk. A systematic review , 2007, Pharmacoepidemiology and drug safety.

[72]  C. Huerta,et al.  Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. , 2007, Archives of internal medicine.

[73]  P. Mitchell,et al.  Statins and the long-term risk of incident age-related macular degeneration: the Blue Mountains Eye Study. , 2007, American journal of ophthalmology.

[74]  P. Mitchell,et al.  Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. , 2007, American journal of ophthalmology.

[75]  R. Schlienger,et al.  Statins and the Risk of Pneumonia: A Population‐Based, Nested Case‐Control Study , 2007, Pharmacotherapy.

[76]  C. Kao,et al.  Cardiovascular Diseases and the Risk of Venous Thromboembolism: A Hospital‐based Case‐control Study , 2007, Journal of the Chinese Medical Association : JCMA.

[77]  Richard W. Murrow,et al.  Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[78]  M Alan Brookhart,et al.  Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.

[79]  L. de Jong-van den Berg,et al.  The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[80]  Frank de Vries,et al.  Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. , 2006, International journal of epidemiology.

[81]  M. Tonelli,et al.  Statins for improving renal outcomes: a meta-analysis. , 2006, Journal of the American Society of Nephrology : JASN.

[82]  Ronald Klein,et al.  Statin use and incident nuclear cataract. , 2006, JAMA.

[83]  M. Nakata,et al.  Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control , 2006, Diabetologia.

[84]  Alicja R Rudnicka,et al.  Statin safety: a systematic review. , 2006, The American journal of cardiology.

[85]  L. Farrer,et al.  Statin use and the risk of Alzheimer’s disease: The MIRAGE Study , 2006, Alzheimer's & Dementia.

[86]  L. Kuller,et al.  Statins and cognitive function in the elderly , 2005, Neurology.

[87]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[88]  J. Gaziano,et al.  Statin use and fracture risk: study of a US veterans population. , 2005, Archives of internal medicine.

[89]  L. Smeeth,et al.  A case control study of age related macular degeneration and use of statins , 2005, British Journal of Ophthalmology.

[90]  Lewis H Kuller,et al.  Statin use and the risk of incident dementia: the Cardiovascular Health Study. , 2005, Archives of neurology.

[91]  B. Horne,et al.  Do statins increase the risk of idiopathic polyneuropathy? , 2005, The American journal of cardiology.

[92]  D. Sparks,et al.  Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. , 2005, Archives of general psychiatry.

[93]  G. Corrao,et al.  Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases , 2004, Journal of Epidemiology and Community Health.

[94]  M. Briel,et al.  Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. , 2004, The American journal of medicine.

[95]  B. Bradbury,et al.  Statins and newly diagnosed diabetes. , 2004, British journal of clinical pharmacology.

[96]  A. Hofman,et al.  HMG‐CoA Reductase Inhibitors and the Risk of Vertebral Fracture , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[97]  L. Merle,et al.  Statins for multiple sclerosis , 2004, The Lancet.

[98]  C. Owsley,et al.  Statins and other cholesterol-lowering medications and the presence of glaucoma. , 2004, Archives of ophthalmology.

[99]  J. Szaflarski,et al.  Hypercholesterolemia, HMG-CoA Reductase Inhibitors, and Risk of Intracerebral Hemorrhage: A Case–Control Study , 2004, Stroke.

[100]  A. Hofman,et al.  Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from 3 continents. , 2004, Ophthalmology.

[101]  B. Psaty,et al.  HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women , 2004, Journal of thrombosis and haemostasis : JTH.

[102]  H. Sørensen,et al.  Hip fracture risk in statin users—a population-based Danish case-control study , 2004, Osteoporosis International.

[103]  G. McGwin,et al.  Association between Statin Use and Alzheimer’s Disease , 2004, Neuroepidemiology.

[104]  M. Mamdani,et al.  Statins and the risk of idiopathic venous thromboembolism. , 2003, British journal of clinical pharmacology.

[105]  H. Jick,et al.  Lipid-lowering drugs and the risk of depression and suicidal behavior. , 2003, Archives of internal medicine.

[106]  C. Curcio,et al.  Complex mutations of USH2A gene denote ARRP , 2003, The British journal of ophthalmology.

[107]  R. Klein,et al.  Relation of statin use to the 5-year incidence and progression of age-related maculopathy. , 2003, Archives of ophthalmology.

[108]  A. LaCroix,et al.  Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women's Health Initiative Observational Study , 2003, Annals of Internal Medicine.

[109]  L. Smeeth,et al.  Cataract and the use of statins: a case-control study. , 2003, QJM : monthly journal of the Association of Physicians.

[110]  R. Collins,et al.  Heart Protection Study , 2003, The Lancet.

[111]  A. Hofman,et al.  Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement , 2003, BMJ : British Medical Journal.

[112]  W A Ray,et al.  Lipid-lowering agents and the risk of hip fracture in a Medicaid population , 2002, Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention.

[113]  P. Wilson,et al.  Heart protection study. , 2002, Current cardiology reports.

[114]  R. Kronmal,et al.  Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. , 2002, Archives of internal medicine.

[115]  J. Hallas,et al.  Statins and risk of polyneuropathy: A case-control study , 2002, Neurology.

[116]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[117]  R. Schlienger,et al.  Risk of cataract in patients treated with statins. , 2001, Archives of internal medicine.

[118]  H. R. Taylor,et al.  Cholesterol‐lowering medications reduce the risk of age‐related maculopathy progression , 2001, The Medical journal of Australia.

[119]  J. Hallas,et al.  Lipid-Lowering Drugs and Risk of Myopathy: A Population-Based Follow-Up Study , 2001, Epidemiology.

[120]  K. Laake,et al.  Statins for the prevention of Alzheimer's disease. , 2001, The Cochrane database of systematic reviews.

[121]  C. Cooper,et al.  Use of statins and risk of fractures. , 2001, JAMA.

[122]  B. Strom,et al.  Statins and fracture risk. , 2001, JAMA.

[123]  C. Schweiger.  [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[124]  J. Hallas,et al.  Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? , 2001, European Journal of Clinical Pharmacology.

[125]  J. Avorn,et al.  HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. , 2000, JAMA.

[126]  H Jick,et al.  HMG-CoA reductase inhibitors and the risk of fractures. , 2000, JAMA.

[127]  Michael J. Goodman,et al.  Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women , 2000, The Lancet.

[128]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[129]  MD I. Elaine Susan D. Ross,et al.  Clinical outcomes in statin treatment trials: a meta-analysis. , 1999, Archives of internal medicine.

[130]  George Davey Smith,et al.  Meta-analysis: Principles and procedures , 1997, BMJ.

[131]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[132]  Humphrey D L Birley,et al.  Implicit memory , 1994, BMJ.

[133]  A. Wear.  CIRCULATION , 1964, The Lancet.

[134]  S. Rosen,et al.  Irritable colon and gallbladder disease. , 1960, Journal of the American Medical Association.

[135]  Xiang Gao,et al.  1.120 A PROSPECTIVE STUDY OF STATIN USE AND RISK OF PARKINSON DISEASE , 2012 .

[136]  S. Bierma-Zeinstra,et al.  Clinical and epidemiological research , 2011 .

[137]  Lun Li,et al.  Statins for primary prevention of venous thromboembolism. , 2011, The Cochrane database of systematic reviews.

[138]  B. J. Gersh.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2011 .

[139]  R. Hubbard,et al.  Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. , 2009, British journal of clinical pharmacology.

[140]  Tianjing Li,et al.  Statins for age-related macular degeneration. , 2009, The Cochrane database of systematic reviews.

[141]  S. Jick,et al.  Use of Statins and the Risk of Parkinson’s Disease , 2008, Drug safety.

[142]  E. Oger,et al.  Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? , 2008, Thrombosis research.

[143]  C. Owsley,et al.  3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study. , 2006, Archives of ophthalmology.

[144]  K. Laake,et al.  Statins for the reduction of risk of Alzheimer's disease. , 2001, The Cochrane database of systematic reviews.